Enhanced GLP-1 signaling due to treatment and/or pathology may contribute to a reduced prevalence of TAAs in T2D, possibly through regulation of inflammatory responses and/or proteolytic activity [18]. Here, GLP1R is linked to type 2 diabetes mellitus.